RESET Study 
PRospective Study to Evaluate EffectivenesS With the NURO‚Ñ¢ PErcutaneous Tibial 
Neuromodulation System in Patients With OAB  
Clinical Investigational Plan Version 1.0 
03-Jun-2016 
[STUDY_ID_REMOVED] 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
  
 
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  PRospective Study to  Evaluate Effectivenes S with 
the NURO ‚Ñ¢ PErcutaneous  Tibial Neuromodulation 
System in Patients with OAB (RESET)  
Clinical Investigation Plan Identifier  1679 
Study Product Name  NURO  System  
Sponsor  Medtronic , Inc.  
7000 Central  Avenue  NE 
Minneapolis, MN  55432 USA 
Document Version  Version 1.0  
Confidentiality Statement  
The information  contained  in this document  is confidential  and the proprietary  property  of Medtronic.  Any 
distribution, copying,  or disclosure without  the prior  written  authorization  of Medtronic  is strictly 
prohibited.  Persons  to whom  the information  is disclosed must  know  that it is confidential and  that it may  
not be further  disclosed by  them.  
   
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 2 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 1. Version History  
Version Summary of Changes  Auth or(s)/Title  
1.0 ‚Ä¢ Not Applicable, New Document  Elizabeth Michaud , Sr. Principal 
Clinical Research Specialist  
2. Investigator Statement  
Participating investigators will be provided with a separate investigator agreement to document their 
obligations and commitment with respect to study condu ct. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 3 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 Table of Contents  
 
1. Version History  ................................................................................................................  2 
2. Investigator Statement  ...................................................................................................  2 
Table of Contents  ...................................................................................................................... 3  
3. Glossary ...........................................................................................................................  5 
4. Synopsis  ...........................................................................................................................  6 
5. Introduction  .................................................................................................................. 10 
5.1. Background  .............................................................................................................  10 
5.2. Purpose  ...................................................................................................................  11 
6. Objectives an d Endpoints  .............................................................................................. 11 
6.1. Objectives  ...............................................................................................................  11 
6.1.1.  Primary Objective(s)......................................................................................................  11 
6.1.2.  Secondary Objective  .....................................................................................................  11 
6.2. Endpoints  ................................................................................................................  12 
6.2.1.  Primary Endpoint  ..........................................................................................................  12 
6.2.2.  Secondary Endpoints  .....................................................................................................  12 
6.2.3.  Additional Measures  ......................................................................................................  12 
7. Study Design  .................................................................................................................. 12 
7.1. Duration  .................................................................................................................. 13 
7.2. Rationale  .................................................................................................................  13 
8. Product Description  .......................................................................................................  13 
8.1. General  ....................................................................................................................  13 
8.2. Manufacturer  ...........................................................................................................  13 
8.3. Intended Population  ...............................................................................................  13 
8.4. Product Return  ........................................................................................................  13 
8.5. Product Accountability  ............................................................................................  14 
9. Selection of Subjects  .....................................................................................................  14 
9.1. Study Population  .....................................................................................................  14 
9.2. Sub
ject Enrollment  ..................................................................................................  14 
9.3. Inclusion Criteria  ....................................................................................................  14 
9.4. Exclusion Criteria  ....................................................................................................  14 
10. Study Procedures ...........................................................................................................  15 
10.1.  Schedule of Events  ..................................................................................................  16 
10.2.  Subject Screening  ...................................................................................................  19 
10.3.  Prior and Concomitant Medications  ........................................................................  19 
10.4.  Subject Consent  ...................................................................................................... 19 
10.5.  Medication Compliance  ...........................................................................................  19 
10.6.  Assessment of Efficacy  ............................................................................................  20 
10.7.  Assessment of Safety  .............................................................................................. 21 
10.8.  Recording Data ........................................................................................................  21 
10.9.  Deviation Handling  .................................................................................................. 22 
10.10.  Subject Withdrawal or Discontinuation  ...............................................................  22 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 4 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 11. Risks and Benefits  .........................................................................................................  23 
11.1.  Potential Risks  ........................................................................................................  23 
11.1.1.  Health Risks  ..............................................................................................................  23 
11.1.2.  NURO System Warnings  .............................................................................................  23 
11.1.3.  NURO System Contraindications  .................................................................................  25 
11.1.4.  NURO System Precautions  ..........................................................................................  25 
11.2.  Potential Benefits  ....................................................................................................  26 
11.3.  Risk-Benefit Rationale  ............................................................................................  26 
12. Adverse Event Assessments  .......................................................................................... 26 
12.1.  Definitions/Classifications  ...................................................................................... 26 
12.2.  Reporting of Adverse Events  ...................................................................................  28 
13. Data Review Committees  .............................................................................................. 29 
14. Statistical Design and Methods  .....................................................................................  29 
14.1.  General Statistical Considerations  .......................................................................... 29 
14.1.1.  Study Sample Size Justification  ...................................................................................  29 
14.1.2.  Description of Baseline variables .................................................................................  30 
14.1.3.  Center Pooling  ...........................................................................................................  30 
14.1.4 . Special Considerations  ...............................................................................................  30 
14.1.5.  Interim Analyses  ........................................................................................................  30 
14.1.6.  Reports  .....................................................................................................................  30 
14.2.  Demographics  .........................................................................................................  30 
14.3.  Primary Objective  ...................................................................................................  30 
14.4.  Secondary Objectives  .............................................................................................. 31 
14.4.1.  Secondary Objective #1  .............................................................................................  32 
14.4.2.  Secondary Objective #2  .............................................................................................  32 
14.5.  Additional Measures  ................................................................................................  32 
15. Ethics  ... ..........................................................................................................................  33 
15.1.  Statement(s)  of Compliance  ...................................................................................  33 
16. Study Administration  .....................................................................................................  33 
16.1.  Monitoring  ...............................................................................................................  33 
16.2.  Medtronic Representative Role  ...............................................................................  33 
16.3.  Data Management  ...................................................................................................  34 
16.4.  Direct Access to Source Data/Documents  .............................................................. 34 
16.5.  Confidentiality  .........................................................................................................  34 
16.6.  CIP Amendments  ....................................................................................................  35 
16.7.  Record Retention  ....................................................................................................  35 
16.8.  Publication and Use of Information  ........................................................................  35 
16.9.  Suspension or Early Termination  ............................................................................  36 
17. References  .....................................................................................................................  37 
18. Appendices  ....................................................................................................................  39 
 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 5 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 3. Glossary  
Term  Definition  
ADE Adverse Device Effect  
AE Adverse Event  
CFR Code of Federal Regulations  
CIP Clinical Investigational Plan  
eCRF Electronic Case Report Form  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
IDE Investigational Device Exemption  
IRB Institutional Review Board  
LOCF Last Observation Carried Forward  
MESA  Medical, Epidemiological, and Social Aspects of 
Aging  
OAB Overactive Bladder  
OABq  Overactive Bladder Symptom Quality of Life 
Questionnaire  
PGI-I Patient Global Impression of Improvement  
PPBC Patient Perception of Bladder Condition  
PTNM  Percutaneous Tibial Neuromodulation  
PTNS  Percutaneous Tibial Nerve Stimulation  
QoL Quality of Life  
Oracle RDC Oracle Remote  Data Capture  
Reportable Adverse Events  Serious, device related, procedure related and  all 
device deficiencies will be considered reportable  for 
this stu dy 
SAGA  Self-Assessment Goal Achievement Questionnaire  
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Events  
TENS  Transcutaneous Electrical Nerve Stimulation  
USADE Unanticipated Serious Adverse Device Effect  
UF Urgency Frequency  
UI Urinary Incontinence  
UUI Urge Urinary  Incontinence  
UPS Urgency Perception Scale  
US United States  
UTI Urinary Tract Infection  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 6 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 4. Synopsis  
Title  PRospective Study to  Evaluate Effectivenes S with the NURO‚Ñ¢ 
PErcutaneous  Tibial Neuromodulation System in Patients with OAB 
(RESET)  
Clinical Study Type  Post-market, on -label  
Product Name  Commercially available External Neuromodulation system              
(‚ÄúNURO System‚Äù, model number 3533)  
Sponsor   Medtronic, Inc.  
Indication under 
investigation  The NURO External Neuromodulation system is intended to treat patients with Overactive Bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.  There are 
no investigational devices used in this study, all study products will be 
used in accordance with the product labeling.
 
Investigation Purpose  To evaluate the NURO system for the treatment of OAB in drug na√Øve patients.
 
Product Status  The NURO system is commercially released for the treatment of patients 
with OAB and associated symptoms of urinary urgency, urinary 
frequency, and urge incontinence.  
Sample Size  Up to 120 subjects consented and qualified to participate in the study.  
Primary Objective  To demonstrate a statistically significant reduction, from baseline 
through 12 percutaneous tibial neuromodulation (PTNM) therapy 
sessions, in the number of urge urinary incontinence (UUI) episodes per day
 
Secondary Objectives ‚Ä¢ Reduction from baseline through 12 PTNM therapy sessions in 
number of voids per day  
‚Ä¢ Change from baseline through 12 PTNM therapy sessions in patient 
reported quality of life outcomes as measured by the Overactive 
Bladder Symptom Quality of Life Questionnaire (OABq)  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 7 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 Additional Measures  ‚Ä¢ Incidence of device or therapy -related adve rse events  
‚Ä¢ Nocturia / Nighttime voiding frequency  
‚Ä¢ Urgency including the Urgency Perception Scale (UPS)  
‚Ä¢ Patient-reported Outcomes:  
o Self-Assessment Goal Achievement Questionnaire (SAGA)  
o Patient Perception of Bladder Condition (PPBC)  
o Patient Global Impression of Improvement (PGI -I) 
Study Design  Prospective, multicenter, single arm study to evaluate changes from 
baseline in OAB symptoms as measured by voiding diaries and patient 
reported outcomes through 12 PTNM therapy sessions.  Safety will be 
evaluated by the collection of reportable adverse events and device 
deficiencies. 
Subjects will be enrolled that have symptoms of OAB and no prior 
treatment with anticholinergics/ antimuscarinics  or beta 3 -agonists 
medications to treat OAB.  
Each subject will complete: an enrollment/baseline visit, 12 therapy 
sessions (each approximately 1 week apart), and a final study visit.  
Inclusion/Exclusion 
Criteria Inclusion Criteria:  
1. 18 years of age or older  
2. Diagnosis of OAB with associated symptoms of UUI and qualify 
with at least 3 episodes of mild, moderate, or severe urgency demonstrated on a 3 -day voiding diary   
3. Experiencing UUI symptoms for at least 3 months  
4. No prior treatment with anticholinergics/ antimuscarinics or beta 
3-agonists medications to treat OAB 
5. Willing and able to accurately complete voiding diaries and questionnaires, attend visits, and comply with the study protocol 
 
6. Willing and able to provide signed and dated informed consent   
Exclusio n Criteria:  
1. Have received anticholinergics/ antimuscarinics  or beta 3 -
agonists medications to treat OAB or advanced therapy 
treatment options for OAB (botulinum toxin injections, sacral 
neuromodulation, or percutaneous tibial nerve 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 8 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 stimulation/ neuromodulat ion) 
2. Have primary stress incontinence or mixed incontinence where 
the stress component overrides the urge component [see enrollment/baseline requirements for use of the Medical, Epidemiological, and Social Aspects of Aging urinary 
incontinence questionnair e (MESA) questionnaire]  
3. Have implantable pacemakers or implantable defibrillators 
4. Use of transcutaneous electrical nerve stimulation (TENS) in 
pelvic region, back or legs  
5. Women who are pregnant or planning to become pregnant during the course of the study  (women of child -bearing potential 
must undergo a pregnancy test, with a clear negative result, prior to first PTNM session)  
6. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance  with the study protocol  
7. Nerve damage that could impact either tibial nerve or pelvic floor function  
8. Subjects prone to excessive bleeding  
9. Inadequate skin integrity in the area of PTNM needle 
placement  
10. History of diabetes unless the diabetes is well- control led 
through diet and/or medications  
11. Have symptomatic urinary tract infection (UTI)  
12. Participation in any research study involving or impacting 
gynecologic, urinary or renal function within the 4 -week period 
prior to or plans to participate during study enrollment  
Study Procedures and 
Assessments  Each subject will complete an enrollment/baseline visit, 12 PTNM 
therapy sessions (each approximately 1 week apart), and a final study 
visit for a total of 14 study -related visits.   
Enrollment/Baseline  
Subject s are considered enrolled at the time the study -specific informed 
consent form is signed.  Each subject must  meet all of the inclusion and 
no exclusion criteria to be eligible to participate in this study.   At the 
enrollment/baseline visit, data will be gathered from subjects including 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 9 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 relevant medical history.  The MESA urinary incontinence questionnaire 
will be used to exclude predominant stress incontinence.  If the 
Investigator‚Äôs assessment differs from the results of the MESA questionnaire, rationale must be documented to explain the decision to enroll the subject.  
 
Subjects will complete the following required questionnaires: OABq, UPS, PPBC, and SAGA at the enrollment/baseline visit.  The 3 -day 
urinary baseline voiding diary, pregnancy test (if of c hildbearing 
potential) must be completed prior to the initial therapy session.   For 
subjects who have dual incontinence (defined as bladder and fecal 
incontinence), a 7 -day fecal incontinence diary will be recommended at 
baseline in addition to the 3 -day urinary voiding diary.  
Weekly PTNM Therapy Session Visits (PTNM Sessions #1- #12)  
At the weekly follow -up visits,  OAB medication(s) and adverse events 
will be collected from the subject.  Following completion of all visit -
specific data collection, subjects will then complete a NURO therapy 
session in accordance with the NURO System Instructions for Use.  
Approximately  one day after PTNM therapy sessions #1, #4, #8 and 
#12, subjects will start their 3 -day urinary voiding diary.  OABq, UPS, 
and PPBC questionnaires will be completed prior to starting PTNM therapy sessions #2, #5 and #9.  Questionnaires must be completed 
prior to the therapy session.   Following completion of all visit -specific 
data collection, subjects will then complete a NURO therapy session.   
Final Study Visit  
At the final study visit, the subject‚Äôs 3 -day urinary voiding diary will be 
collected.   For  subjects who have dual incontinence, a 7 -day fecal 
incontinence diary will be recommended in addition to the 3 -day urinary 
voiding diary.  Any OAB medication(s) and adverse events will be 
collected from the subject. Subjects will complete the required questionnaires associated with the OABq, UPS, PPBC, SAGA and PGI -I.   
Subjects will then be exited from study.   
 
Safety Assessments  Safety will be evaluated by the collection of reportable adverse events.  
Statistics  The sample size estimate is based on a one -sample t -test, with Œ±=0.05 
two-sided, 90% power and an estimated standard deviation of 2.2 UUI 
episodes/day. If the mean reduction in number of UUI episodes is expected to be .75 per day after 12 PTNM therapy sess ions compared to 
baseline, a sample size of 93 subjects would be required to demonstrate 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 10 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 a statistically significant reduction from baseline. To account for subject 
attrition over the period of the study, additional subjects will be enrolled 
for a sample size of up to 120 consented and qualified subjects.  
5. Introduction   
This prospective, open -label clinical study using the NURO System  will be conducted in approximately 120 
subjects with UUI, and will include approximately 15  study sites in the United States  (US).  The expected 
study commitment for each subject is a pproximately 14  weeks, including the baseline  and final study  
visits.   The study will be conducted in accordance with this protocol, the ethical principles that have their 
origin in the Declaration of Helsinki, all applicable regulatory requirements (21  Code of Federal 
Regulations  [CRF]  ¬ß50 Protection of Human Subjects , and 21CFR¬ß56 Institutional Review Board [IRB] 
and 21CFR¬ß 803 Medical Device Reporting ), and in accordance with Good Clinical Practice (GCP).  This 
study will be posted on ClinicalTrials.gov as part of Medtronic‚Äôs commitment to full disclosure for ongoing studies that meet the requirements for public posting.  
Documentation for this study will be produced and maintained to ensure that a complete history of the study exists.  Documents created for this study, including all versions and translations of original documents, will be identifiable and appropriately stored to assure control and traceability of data related 
to this study.   
5.1. Background  
The American Urological Association Guideline s for the diagnosis and treatment of OAB in adults provides 
a clinical framew ork for the diagnosis and treatment of non -neurogenic OAB. The guidance lists Percuta -
neous Tibial Nerve Stimulation (PTNS), otherwise known as Percutaneous Tibial Neuromodulation 
(PTNM ), as an accept able treatment in a carefully selected patient characterized by moderately severe 
baseline incontinence and frequency and willingness to comply with the PTNM protocol.1 
The most common therapy protocol is the application of 30 minutes of stimulation once per week for 12 
weeks  based on early work done by Govie r et al. 2 and thus 12 weekly treatment sessions is the duration 
of the majority of published studies.  
The safety of PTNM has been reported extensively in the literature.2-8  These studies range in size from 
35 patients6 to 110 patients7 receiving active treatment over a 12 week period.  The reported treatment -
related adverse events were described as generally mild and transient (such as discomfort at the needle 
site, minor bleeding, bruising, cramping); none needing surgical intervention  to resolve.  Published 
randomized controlled trials have been conducted comparing PTNM to sham6,7 or PTNM to 
pharmacological treatment.4,5,8 Overall, PTN M improved key objective efficacy outcomes of incontinent 
episodes and voiding frequency4-8 along with  patient‚Äôs quality of life  compared to baseline.5-8  PTNM  was 
observed to be superior to sham regardless of the endpoint definition  (objective or subjective)6,7; 
however, n o statistically -significant differences were observed between PTNM  and medication in terms of 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 11 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 voiding symptom improvement and Quality of Life  (QOL).5 One study indicated a greater degree of 
efficacy in PTNM compared to medications.8 
Multiple systematic reviews have been published on the performance of PTNS for OAB9-13, and conclude  
that PTNM is safe and effective for treating OAB.  Additionally, PTNM  appears in medical treatment 
guidelines in the United States1 and Internationally .14,15  Since  the the NURO device delivers identical 
stimulation therapy as the PTNS device evaluated in the literature, a user can expect similar performance 
as that reported in the clinical literature.  
Published literature has primarily focused on OAB drug refractory populations; however , in a study by 
Preyer et al. (2015), 36 treatment na√Øve subjects were rand omized between PTNM and pharmacological 
treatment.16   In this patient population, PTNM reduced incontinence episodes and improved Q OL in 
patients with OAB  to a similar degree to those patients receiving pharmacological treatment.  This study 
provided an initial example of how drug na√Øve patients may respond to PTNM therapy, however additional 
clinical work is needed to characterize drug na√Øve patients and bett er understand their treatment 
response to PTNM.  
5.2. Purpose  
The purpose of this prospective, multicenter, single arm study is to evaluate the NURO system for the 
treatment of OAB in drug na√Øve patients.  The study will assess change from baseline through  12 PT NM 
therapy sessions in UUI episodes, voiding episodes, and patient reported outcomes.  Safety will be 
evaluated by the collection of reportable adverse events.  The study is expected to last approximately 14  
weeks per subject following the enrollment visit .  Subject s will be  exited from the study after the final 
study visit is complete. 
6. Objective s and Endpoints  
6.1. Objectives  
6.1.1.  Primary Objective (s) 
The primary objective of this study is to assess the efficacy of PTNM on UUI episodes in drug na√Øve 
patients with OAB . 
6.1.2.  Secondary Objective  
Secondary objectives of this study are to assess the improvement on number of voids per day and QOL 
measures in drug na√Øve patients with OAB.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 12 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 6.2. Endpoints 
6.2.1.  Primary Endpoint  
The primary objective of this study is to demonstrate a statistically significant reduction from baseline  
through 12 PTNM  therapy sessions in the number of UUI episodes per day.  
6.2.2.  Secondary Endpoints  
Secondary objectives include:  
‚Ä¢ Reduction from baseline  through 12 PTNM therapy sessions in number of voids per day  
‚Ä¢ Change  from baseline  through 12 PTNM therapy sessions in quality of life  as measured by the 
Overactive Bladder Symptom Quality of Life Questionnaire  (OABq)  
6.2.3.  Additional Measures  
Additional measures include:  
‚Ä¢ Incidence of device or therapy -related  adverse events  
‚Ä¢ Nocturia / Nighttime voiding frequency   
‚Ä¢ Urgency including the Urgency Perception Scale (UPS)  
‚Ä¢ Patient-reported Outcomes:  
ÔÇß Self-Assessment Goal Achievement Questionnaire  (SAGA) 
ÔÇß Patient Perception of Bladder Condition  (PPBC) 
ÔÇß Patient Global Impression of Improvement (PGI -I) 
7. Study Design   
This is a prospective, multicenter, open -label study evaluating the use of PTNM in OAB drug na√Øve 
patients with UUI.  
All eligible subjects will sign a study -specific informed consent form (ICF).  Following qualification using a 
baseline diary, subjects will undergo 12 PTNM therapy sessions, administered weekly,  utilizing the NURO 
system.  Urinary voiding diaries (3 -day) to assess efficacy measures and quality of life questionnaires will 
be completed after therapy session s as required in  Figure 1- 1: Study Procedures .  The study is expected 
to last approximately 14 weeks per subject following the baseline/enrollment visit.  Subjects will be exited from the study after the final study visit is complete.  
The required sample size is 120 consented and qualified subjects; which includes 93 subjects required to 
meet the study endpoint and approximately 20% to account for potential attriti on.  
The study will be conducted at approximately 15 sites in the US.  Initial site enrollment is not planned to exceed 20% of the total number of subjects enrolled to reduce the possibility that a site with atypical results will be overly influential in t he overall study results based on pooled data; however this may be 
increased based on the Sponsor‚Äôs discretion.   
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 13 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 This is an on -label, post -market study of an FDA -cleared device that is exempt from Investigational 
Device Exemption (IDE) require ments under 21 CFR 812(c)(2).  All subjects enrolled in the study will 
qualify under the approved indication for the NURO system.  
7.1. Duration  
Study subjects will be enrolled and will complete enrollment/baseline requirements to determine 
eligibility.  Subjects that do not qualify for the study prior to the first PTNM therapy session will be exited 
from the study.  All enrolled subjects that qualify for the study (meet all inclusion and no exclusion) will 
receive  12 PTNM therapy sessions, each approximately 1 week apart , prior to completing the final study 
visit.  The visits are expected to occur over a 14 week period.  
7.2. Rationale  
While there is extensive literature on the safety and efficacy of PTNM, the majority of published literature 
is on OAB drug refractory patients.  The purpose of this study is to understand the effect of PTNM in a 
OAB drug na√Øve patient population.  The NURO system is cleared by the Food and Drug Administration 
(FDA) and will be used in accordance with commercially available product labeling.  
8. Product Description  
8.1. General  
The NURO system includes: the NURO External Neurostimulator (model 3533), Therapy Sessions (model 3533S), and single -use Therapy Session Kits (model 3533K) which are provided separately.  The Therapy 
Session Kit includes: two sterile needles, two alcohol wipes, a needle holder, and ground pad. The NURO device is a small and portable pulse generator, and should only be used with the single -use items listed 
above. The system also includes a wall charger and USB cable.  Sites will need  to ensure technical 
compatibility with the NURO e -commerce site in order to activate the device and download and transfer 
therapy sessions to the NURO External Neurostimulator.  
8.2. Manufacturer 
The products used in this study, identified in  Section 8.1, are manufactured by Medtronic, Inc. and are 
approved for use in treating patients with OAB.  
8.3. Intended Population  
The study will enroll OAB drug na√Øve patients with a diagnosis of OAB and associated symptoms of UUI 
(see Section 9). 
8.4. Product Return  
Since all products are commercially available, product associated with a complaint should be returned through commercial processes.  Contact your study team member for return instructions.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 14 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 8.5. Product Accountability  
All product used in the study  are commercially available; therefore no product accountability will be 
required for the study .  
9. Selection  of Subjects  
9.1. Study Population  
The intended study population is subjects with UUI who have not tried an OAB medication.  In addition, 
subjects must  not have received advanced therapy treatment options for OAB (botulinum toxin injections, 
sacral neuromodulation or PTNS/PTNM).   
9.2. Subject Enrollment  
Subjects are considered enrolled at the time the study -specific ICF is signed.  Each subject must meet all 
of the inclusion criteria  and no exclusion criteria  to be eligible to participate in this study.  Any subject 
meeting an exclusion  criterion will be excluded from study participation.  
9.3. Inclusion Criteria  
In order to be eligible to participate in the study, a subject must meet all of the following inclusion 
criteria:  
1. 18 years of age or older  
2. Diagnosis of OAB and associated symptoms of UUI and qualify with  at least 3 episodes of 
mild, moderate, or severe urgency  demonstrated on a 3-day urinary  voiding diary  
3. Experiencing UUI  symptoms for at least 3 months  
4. No prior treatment with anticholinergics/ antimuscarinics  or beta 3 -agonists medications 
to treat OAB  
5. Willing and able to accurately complete voiding diaries and questionnaires, attend visits, 
and comply with the study protocol  
6. Willing and able to provide signed and dated informed consent  
9.4. Exclusi on Criteria  
A potential subject who meets any of the following criteria will be excluded from participating in the 
study:  
1. Have received  anticholinergics/ antimuscarinics  or beta 3 -agonists medications to treat 
OAB or advanced therapy treatment options for OAB (botulinum toxin injections, sacral 
neuromodulation, or percutaneous tibial  nerve stimulation/ neuromodulation)  
2. Primary stress incontinence or mixed incontinence where the stress component overrides 
the urge component  (see enrollment/baseline requirements for use of the MESA urinary 
incontinence questionnaire)  
3. Have implantable pacemakers or implantable defibrillators 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 15 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 4. Use of transcutaneous electrical nerve stimulation (TENS) in pelvic region, back or legs 
5. Women who are pregnant or planning to become pregna nt during the course of the 
study (women of child -bearing potential must undergo a pregnancy test, with a clear 
negative result, prior to first PTNM session )  
6. Characteristics indicating a poor understanding of the study or characteristics that 
indicate the  subject may have poor compliance with the study protocol  
7. Nerve damage that could impact either tibial nerve or pelvic floor function.  
8. Subjects prone to excessive bleeding  
9. Inadequate skin integrity in the area of PTNM needle placement  
10. History of diabetes unless the diabetes is well- controlled through diet and/or medications  
11. Have symptomatic urinary tract infection (UTI)  
12. Participation in any research  study involving or impacting gynecologic, urinary or renal 
function within the 4 -week period prior to or pla ns to participate during study enrollment  
10. Study Procedures   
The study schedule, procedures, and methods of assessment are defined in detail to enable compliance 
with the required activities, and to ensure that the resulting data meet the criteria for evalu ability.   See 
Table 1 -1 for visit requirements.  Both paper and electronic case report form (eCRF) will be provided for 
use in collecting data for all subjects; the  pertinent eCRFs along with the applicable source 
documentation will be completed for each subject.  
Enrollment/Baseline  
Subjects are considered enrolled at the time the study -specific ICF is signed.  Each subject must meet all 
of the inclusion criteria and no exclusion criteria to be eligible to continue participation in this study.    
As part of the inclusion/exclusion evaluation, the MESA urinary incontinence questionnaire will be used to 
exclude predominant stress incontinence.  If the Investigator‚Äôs assessment differs from the results of the 
MESA questionnaire, rationale must be documented to explain the decision to enro ll the subject.  
Additionally, prior and ongoing conservative therapies for OAB such as physical therapy, pelvic floor 
muscle training, behavior modification, and dietary programs and relevant medical history will be 
assessed at baseline tracked throughout  the duration of the study .  Subjects will be encouraged to 
continue any conservative therapies for OAB they were on at entry through the duration of the study . 
Subjects will complete the following required questionnaires: OABq, UPS, PPBC, and SAGA at the 
enrollment/baseline visit.  The 3 -day baseline urinary voiding diary and pregnancy test (women of child -
bearing potential must undergo a pregnancy test, with a clear negative result) must be completed prior to the initial therapy session.  For subjects who  have dual incontinence, an additional 7 -day fecal 
incontinence diary will be recommended at baseline.   
The baseline urinary voiding diary is to be completed and returned to confirm remaining eligibility criteria.  If the subject does not meet eligibility  criteria of at least 3 UUI episodes demonstrated on a 3 -day voiding 
diary, the subject must be exited from the study.  
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 16 of 39 
Confidential  
Version 1.0              Medtronic RESET Protocol  June 2 , 2016  
 Initial PTNM Therapy Session ( PTNM Session #1)  
The baseline urinary voiding diary must be reviewed to confirm eligibility prior to begin ning the initial 
PTNM therapy session.  If the subject does not meet eligibility criteria of at least 3 UUI episodes 
demonstrated on a 3 -day voiding diary, the subject must be exited from the study.  Any OAB 
medication(s), conservative therapies for OAB an d reportable adverse events will be collected from the 
subject.   
If the subject meets the eligibility criteria of at least 3 UUI episodes of mild, moderate, or severe urgency 
demonstrated on a 3 -day voiding diary, the subject will then complete a PTNM therapy session using the 
NURO device.  The PTNM therapy sessions will be completed in accordance with the NURO System 
Instructions for Use.  
Weekly PTNM Therapy Session s: PTNM Sessions #2 -#12  (1 Week ¬± 3 days)  
At the weekly follow -up visits,  any  OAB medication(s), conservative therapies for OAB and reportable 
adverse events will be collected from the subject.  Subjects will then complete a PTNM therapy session 
with the NURO device used in accordance with the NURO system Instructions for Use.  
Three -day voiding diaries will be provided to the subjects to be started approximately one day after 
PTNM Session #1, PTNM Session #4, PTNM Session #8, and PTNM Session #12.  
At PTNM Session #2, PTNM Session #5 and PTNM Session #9, and the final visit subjects will return their 
completed 3 -day urinary voiding diary and complete OABq, UPS and PPBC questionnaires.  Subjects are 
required to complete the questionnaires prior to the PTNM therapy session. Subjects will then complete a PTNM therapy session with the NURO device used in accordance with the NURO system Instructions for 
Use. 
After PTNM Session #12, a 3 -day urinary voiding diary will be provided for the subject to start 
approximately one day after the therapy session.  Subjects who have dual incontinence that completed 7 -
day fecal incontinence diary at baseline be provided with a final 7 -day fecal incontinence diary.  
Final Study Visit (1 Week ¬± 3 days)  
At the final study visit, the completed final 3 -day urinary voiding diary, 7 -day fecal incontinence dia ry (if 
applicable), any OAB  medication (s), conservative therapies for OAB  and reportable adverse events will be 
collected from the subject.  Subjects will complete the following required questionnaires: OABq, UPS, 
PPBC,  PGI-I, and SAGA. Following collection of all study -related data, the subject will be exited from the 
study .  
10.1.  Schedule of Events  
The start of the study is defined as the date the  subject first signs the informed consent.  The completion of the study for each subject is defined as the completion of the  final study visit. S ubjects that 
do not qualify for the study prior to the first PTNM therapy session  will be exited from the study .  The 
completion of the study is defined as the completion of the Final Study Report and  closure of all sites.   
  
)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI
&RQILGHQWLDO
9HUVLRQ 0HGWURQLF5(6(73URWRFRO -XQH
)LJXUH6WXG\3URFHGXUHVLOOX VWUDWHVUHTXLUHGVWXG\SURFHGX UH
)LJXUH6WXG\3URFHGXUHV 
Qualification
Eligible to 
ParticipateStudy Discontinuation
If subject does not meet 
all inclusion and no 
exclusion criteriaEnrollment 
Signed Consent
Final Study VisitBaseline
¬Ñ  Verification of Inclusion/Exclusion Criteria 
¬Ñ  Medical History    ¬Ñ Pregnancy Test
¬Ñ Collect 3-day Voiding Diary ¬Ñ MESA Questionnaire
¬Ñ Collect 7-day Fecal Incontinence Diary (for dual incontinence)
¬Ñ  Assessment of Conservative OAB Therapy
Questionnaires:
¬Ñ OABq         ¬Ñ UPS    ¬Ñ  PPBC       ¬Ñ SAGA
¬Ñ  Collect 3-day Voiding Diary
Questionnaires Completed Prior to PTNM 
Therapy Session:
¬Ñ OABq         ¬Ñ UPS    ¬Ñ PPBC       
¬Ñ  AE Assessment
¬Ñ  OAB Medication Assessment
¬Ñ  Assessment of Conservative OAB Therapy
¬Ñ Collect 3-day Voiding Diary
¬Ñ Collect 7-day Fecal Incontinence Diary 
 (for dual incontinence)
Questionnaires:
¬Ñ OABq      ¬Ñ UPS  ¬Ñ  PPBC
¬Ñ SAGA    ¬Ñ PGI-I¬Ñ AE Assessment
¬Ñ OAB Medication Assessment
¬Ñ Assessment of Conservative OAB Therapy
  PTNM Therapy Sessions #1 - #12
Note: Voiding diaries should be 
provided to subjects at PTNM sessions 1, 4, 8 and 12 for completion 1 day after the visit.YesNo
PTNM Therapy          
Sessions #2, #5, #9

056-F275, Clinical Inves tigation Plan Template, Version 2.0    Page 18 of 39 
 
Confidential  
Version 1.0  Medtronic RESET Protocol  June 2 , 2016  
 A detailed table of the study procedures, presenting the type of procedure required at each visit, is presented in Table 1 -1. 
Table 1 -1: Study Proced ures  
Procedures   Enrollment/  
Baseline Visit  
 PTNM 
Session 
#1 PTNM 
Session 
#2 PTNM 
Session 
#3 PTNM 
Session 
#4 PTNM 
Session 
#5 PTNM 
Session 
#6 PTNM 
Session 
#7 PTNM 
Session 
#8 PTNM 
Session 
#9 PTNM 
Session 
#10 PTNM 
Session 
#11 PTNM 
Session 
#12 Final 
Study Visit  
Informed Consent Form  X              
Inclusion/Exclusion  X X             
Pregnancy Test*    X*              
Reportable Medical History  X              
Distribute Urinary Voiding 
Diary X X   X    X    X  
Distribute Fecal 
Incontinence  Diary**  X            X  
Collect Urinary Voiding 
Diary      X*** X   X    X    X 
Collect Fecal Incontinence  
Diary **   X            X 
OABq Questionnaire  X  X   X    X    X 
UPS Questionnaire  X  X   X    X    X 
PPBC Questionnaire  X  X   X    X    X 
PGI-I Questionnaire               X 
SAGA Questionnaire  X             X 
Conservative Therapies for 
OAB X X X X X X X X X X X X X X 
AE Review  X X X X X X X X X X X X X X 
OAB Medication Review  X X X X X X X X X X X X X X 
*For women of child bearing potential  to be completed prior to the first PTNM therapy session  
**Fecal incontinence   Diary (7 -day) is recommended for subjects with dual incontinence  
***Qualification diary must be reviewed to confirm eligibility prior to beginning first PTNM therapy session   
 
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 19 of 39 
 
Confidential  
Version 1.0  Medtronic RESET Protocol  June 2, 2016  
 10.2.  Subject Screening  
Subjects may be recruited through the investigator‚Äôs practice and referring physicians.  
Potential subjects may be identified through chart reviews or as new or existing patients attend clinic 
visits.  If subjects a re recruited from outside the investigator‚Äôs practice, sites are to ensure that 
appropriate release for access to the subject‚Äôs records  (paper and/or electronic)  is obtained. Any subject  
recruitment materials disseminated to subjects (advertisements, hando uts, posters , social media ) must 
be approved by the IRB prior to use.  
Recruited subjects will be screened by the Principal Investigator or authorized site personnel by reviewing 
the study‚Äôs inclusion and exclusion criteria.  All subjects must be consented  in accordance with the 
protocol  prior to any study -specific procedures.  
As part of the inclusion/exclusion evaluation, the MESA urinary incontinence questionnaire will be used to exclude predominant stress incontinence.  If the Investigator‚Äôs assessment d iffers from the results of the 
MESA questionnaire, rationale must be documented to explain the decision to enroll the subject .  
10.3.  Prior and Concomitant Medications  
Subject s may not be enrolled if they have had any prior treatment with anticholinergic /antimuscarinic or 
beta 3 -agonist medications to treat OAB . 
10.4.  Subject Consent  
The informed consent process will be performed in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki and with 21CFR¬ß50 Protection of Human Subjects.  
Prior to entering the study, the Principal I nvestigator or qualified designee will explain to each subject the 
purpose and nature of the study, procedures, expected study duration, available alternative therapies, and the benefits and risks invol ved with study participation and the potential treatment.  Subjects will be 
given a copy of the IRB -approved ICF and will have time to review the document and to ask questions 
and will be informed of their right to withdraw from the study at any time witho ut prejudice; ICFs will be 
provided in a language understandable to the subject.  After this explanation and before any study -
specific procedures have been performed, the subject will voluntarily sign and date the ICF.  Prior to 
participation in the study,  the subject will receive a copy of the signed and dated written informed 
consent and any other written information provided to the subject.  
The Principal I nvestigator or qualified (delegated)  designee will document the informed consent process, 
including the date of consent and name of the person conducting the consent process in the subject‚Äôs medical record.  A copy of the signed ICF will also be placed in the subject‚Äôs medical record.  
10.5.  Medication Compliance  
Subject s eligible to participate must be  OAB dru g na√Øve.   
If a subject starts an OAB medication prior to starting the PTNM therapy sessions, they should be considered ineligible for the study and should be exited.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 20 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 If a subject starts anticholinergic/ antimuscarinic or beta 3 -agonist medications to treat OAB  following 
their first PTNM therapy session a  deviation form will be completed and this medication will be captured 
on the OAB medication form.  
Medications used to treat reportable  adverse events will be documented as ‚Äúinterventions‚Äù on the 
adverse event case report form.   
10.6.  Assessment of Efficacy  
Subject assessments will be performed by appropriately trained, qualified and delegated site personnel 
according to the usual practices of the site.  
Medical History and Demographics  
Assessments will be  completed and  reported on the eCRF.  
Urinary Voiding Diary  
Symptoms related to OAB will be evaluated using paper voiding diaries.  Subjects will be trained to 
complete the urinary voiding diaries for 3 -days as part of the baseline procedures and instructed to 
start the voiding diary approximately 1 day after PTNM Session #1, #4, #8  and #12.  These voiding 
diaries will then be collected at the next following PTNM Session. Every effort should be made to 
remind subjects of the importance of real-time diary completion.  
Voiding diary data will be used to verify study inclusion criteria for UUI episodes at baseline.  Diaries 
will also be used for comparison to baseline for  the primary study endpoint of UUI, secondary study 
endpoint of urgency frequency ( UF) and additional measure s related to urgency , nocturia and 
nighttime frequency . As clinically defined, nocturia will be measured as the number of times the 
subject is woken from sleep to void.17   Nighttime frequency will be defined as number of voids du ring 
nighttime sleep.17   
Fecal Incontinence  Diary  
It is recommended that subjects with dual incontinence complete a 7 -day fecal incontinence  diary 
during baseline procedures and after 12 PTNM therapy sessions.  
PTNM Therapy Sessions  
Subjects will receive 12 weekly PTNM therapy sessions following the enrollment/baseline visit.   
Assessments for Quality of Life Measures  
Subjects will complete the study questionnaires confidentially on paper forms without site personnel 
consultation and these data will be entered to OC/RDC by site personnel.    Questionnaires should be 
completed prior to the initiation of the PTNM therapy session. Site personnel are encouraged to review forms for completeness.  
Overactive Bladder Quality o f Life Questionnaire (OABq)  
The Overactive Bladder Quality of Life Questionnaire (OABq) is a 33 -item questionnaire that was 
developed to assess symptom bother and the impact of overactive bladder (OAB) on health -related 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 21 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 quality of life (HRQL ).18  The ques tionnaire used in the current study includes a 1 -week recall for 
symptom assessment.  
Urgency Perception Scale (UPS)  
The Urgency Perception Scale (UPS) is a single item questionnaire measure of perceived urinary 
urgency with three response options .19,20   
Self-Assessment Goal Achievement Questionnaire (SAGA)  
Patient attainment goals have been used throughout the liter ature in order to determine if patients 
are reaching pre -determined goals.21,22  The Self -Assessment Goal Achievement (SAGA) 
questionnaire is a tool designed to help patients with low er urinary tract symptoms  assess goal 
achievement.23  The SAGA questionnaire allows for the patient to rank , in order of importance for 
standard urology symptom goals using a scale of 0 -5 and allows for other person al goals to be 
included.  After treatment has been completed, the patient then completes the follow -up 
assessment which includes a scale of - 2 to 2 to report on achievement of each symptom goal and 
personal goal(s).   The questionnaire includes an assessme nt question of ‚ÄúOverall, to what extent 
have you achieved your goals‚Äù on a scale of 0-4.  
Patient Perception of Bladder Condition (PPBC)  
The Patient Perception of Bladder Condition (PPBC) is a single -item, 6 -point scale that asks patients 
to rate their subjective impression of their current bladder problems.24,25   
Patient Global Impression of Improvement (PGI-I) 
Overall impression for improvement is evaluated using the Patient Global Impression of 
Improvement (PGI -I)26-28  which is a single question ask ing the patient to rate their urinary 
condition now  as compared with prior to beginning treatment on a scale from 1  (very much better) 
to 7 (very much worse ). 
10.7.  Assessment of Safety  
Subjects will be assessed for potential reportable adverse events that are reportable under the study 
protocol at each study visit.  
10.8.  Recording Data  
This study will be conducted using a remote data capture system .  The Oracle Clinical Remote Data 
Capture (RDC) system which allows the study centers to enter study data into the spons or‚Äôs database 
over a secure internet connection, will be used to capture study required Case Report Form (CRF) 
information.   Paper CRFs will be utilized for voiding diaries and subject questionnaires only; however data 
will be entered to the database by site personnel.  Subjects will complete the study questionnaires 
confidentially on paper forms  without site personnel  consultation and these data will be entered to 
OC/RDC by site personnel.   Electronic CRFs (eCRFs) will be provided by the sponsor; required data will be 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 22 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 taken from source documents and directly entered into the study database via the CRFs by the site 
personnel, in accordance with applicable regulations.  
Subject voiding diaries and questionnaires are to be completed only by the subject.  Representatives from 
the research site may not make changes to the diaries or questionnaires with the exception of 
administrative entries and clarification on source documentation.  
The Principal or Sub -Investigator, or an individual delegated by the Principal Investigator on the 
Delegation of Authority and Signature Form , is responsible for documenting and entering data  for the 
study  on the eCRFs.  The Principal Investigator or Sub -Investigator is required to approve all data on 
CRFs via electronic signature.  
10.9.  Deviation  Handling  
Protocol deviations are digressions from the written protocol defined as an event where the clinical 
investigator or site personnel did not conduct protocol- required procedures according to the study 
protocol.   Protocol deviations are to b e preapproved by Medtronic study personnel and the IRB (as 
required)  unless the deviation is necessary to protect the health, safety, or welfare of a subject in an 
emergency situation.  The investigator or delegated site personnel should immediately contact the 
designated Medtronic study personnel to discuss the impact of the potential deviation; prior approval of 
deviations should be documented.  Prior approval is generally not required if the deviation is due to an 
emergency circumstance or an unforeseen circumstance that is beyond the investigator‚Äôs control; 
however, these deviations should be reported to Medtronic and the IRB (as required)  after site personnel 
become aware of the devia tion.  All protocol deviations must be reported on the Protocol Deviation eCRF 
after the site‚Äôs awareness of the deviation.    
The sponsor may choose to terminate the study at a site for failure to follow the written protocol and 
investigator agreement.  I f this occurs, the Investigator and IRB will be notified in writing of the reasons 
for the termination.  
10.10.  Subject Withdrawal or Discontinuation  
Subjects are free to voluntarily withdraw from the study at any time and for any reason.  The investigator 
can wi thdraw a subject from the study at any time and  for any reason.  Withdrawn or exited  subjects will 
be followed under normal medical practice.  
Examples of reasons for study discontinuation include, but are not limited to, those listed below:  
‚Ä¢ If the subject does not meet eligibility criteria of at least 3 UUI episodes of mild, moderate, or 
severe urgency  demonstrated on a 3 -day urinary voiding diary  
‚Ä¢ Subject death  
‚Ä¢ Subject lost to follow -up 
‚Ä¢ Subject voluntarily withdraws from the study  
‚Ä¢ Subject be comes pregnant  
‚Ä¢ Investigator terminates the subject‚Äôs participation in the study due to lack of compliance, 
violation of/change in eligibility criteria  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 23 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 ‚Ä¢ Any clinical laboratory abnormality, inter -current illness, or other medical condition or situation 
occur s such that continued study participation would not be in the best interest of the subject. 
‚Ä¢ Subject is not a candidate for PTNM therapy  
‚Ä¢ Normal study completion  
Prior to deeming a subject lost to follow -up, telephone calls must be documented in the subjec t‚Äôs medical 
record. If a minimum of three attempts to contact the subject have failed  (e.g. phone and mailed letter), 
and no response is received, the site should exit  the subject and complete the Study Discontinuation 
eCRF.  
When a subject is withdrawn from the study, the Study Discontinuation eCRF is  to be  completed and 
should include detailed notes as to why the subject was withdrawn  from the study (e.g., discomfort, lack 
of efficacy, diary too burdensome).  There is no further medical care provided under  the study after a 
subject exits from the study.  
11. Risks and Benefits  
11.1.  Potential Risks  
11.1.1.  Health Risks  
The following are known potential health risks associated with the NURO system and PTNM therapy : 
‚Ä¢ Discomfort and pain (including throbbing pain) at, or near, th e stimulation site, including the 
patient's lower leg and foot  
‚Ä¢ Bleeding at the needle site  
‚Ä¢ Redness/inflammation at, or near, the stimulation site  
‚Ä¢ Numbness of toes  
‚Ä¢ Stomach ache  
11.1.2.  NURO System Warnings  
To avoid risks to study subjects and system users, Investig ators and site personnel should be aware of 
the following . 
1. The provided Instructions for Use is NOT a comprehensive reference to therapeutic techniques 
for the indications noted for the NURO system.  Section 1 1.1 will only be revised based on 
significant n ew safety information added to the Instructions for Use.  Refer to the current 
Instructions for Use for complete contraindications, warnings and precautions.  
2. Investigators and site personnel should be familiar with appropriate application and techniques 
involved in the use of the NURO system and needle in the delivery of Percutaneous Tibial Neuromodulation.  
3. Do not use the NURO system or needle if the skin in th e area of use is inflamed, infected, or 
otherwise compromised. Monitor subjects  during therapy session for pain or skin 
irritation/inflammation. Discontinue use of the NURO system if the subject complains about these symptoms or any other discomfort.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 24 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 4. Do no t use any part of the NURO system to apply stimulation across or through the head, directly 
on the eyes, covering the mouth, on the front of the neck (especially the carotid sinus), or on the 
chest, upper back or crossing over the heart. The application of  the ground pad near the thorax 
may increase the risk of cardiac fibrillation.  
5. Subjects should not spend more than 30 minutes in therapy mode during a single therapy 
session. 
6. The subject should remain comfortably seated, or in a supine position, for the du ration of the 
therapy session. The subject should not rise or walk until the therapy session is complete, because mobility during therapy session has not been assessed.  
7. Do not use the NURO system if any component or accessory is loose or damaged, including  the 
rear electrode snap or internal battery.  
8. Do not use the NURO system if its packaging has been opened or altered. If packaging has been opened or altered, contact Medtronic.  
9. Do not reuse the single -use needle, needle holder, or ground pad.  
10. Dispose of u sed needle, needle holder, and ground pad accessories in bio -hazardous material 
disposal container.  
11. Simultaneous connection of a patient to high frequency surgical equipment may result in burns at the site of the ground pad and/or needle and possible damag e to the NURO device.  
12. Device operation in close proximity (e.g. 1 meter) to short wave or microwave therapy equipment may produce instability in the NURO device output.  
13. The NURO device has electric shock protection, type ‚ÄúInternally Powered Equipment‚Äù per IEC 
60601 -1. 
14. The NURO device enclosure is type IPX0 and does not protect against the ingress of water. Do not use the NURO device in or around water.  
15. For recharging, only use the wall charger provided with the NURO device. Use of a different charger could result in electrical shock or damage to the device.  
16. Do not operate the NURO device with anything plugged into the USB port. Do not insert the needle into the micro USB port.  
17. The following are known potential health risks associated with this type of device  and therapy: 
discomfort and pain near needle site, bleeding near needle site, redness/inflammation near needle site, numbness in toes, and stomach ache.  
18. The NURO device has no serviceable parts. No modification is allowed. Opening the case could lead to e lectrical shock, device damage, or other risks.  
19. Do not exceed the recommended therapy session time of 30 minutes per session.  
20. Do not excessively bend or kink the device cable. Always inspect device cable for signs of wear or damage before use. If wear or d amage is found, discontinue use and return the NURO device to 
Medtronic.  
21. No modification of this equipment is allowed.  
22. Use only the ground pad listed in the IFU. This pad is sized to not to exceed 2 mA/cm2 for the NURO device.  
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 25 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 11.1.3.  NURO System Contraindications 
In order for therapy to be effective and to avoid any possible problems or complications, the NURO 
system is contraindicated for use on patients who have the following history or conditions (see study exclusion criteria):  
1. Subjects prone to excessive bleeding  
2. Subjects with pacemakers or implantable defibrillators  
3. Subjects with nerve damage that could impact either percutaneous tibial nerve or pelvic floor 
function  
4. Subjects who are pregnant or planning to become pregnant whi le using this product  
5. The NURO system is not intended for intra -cardiac or trans -thoracic use.  
6. Concurrent use of medical monitoring equipment during stimulation is not recommended.  
7. The NURO system is not suitable for use in the presence of a flammable anes thetic mixture with 
air or with oxygen or nitrous oxide.  
11.1.4.  NURO System Precautions  
‚Ä¢ Prior to using the NURO system, read and understand all instructions.  
‚Ä¢ Caution should be used for patients with suspected or diagnosed heart problems, especially those 
relating to the pacing or electrical functioning of the heart.  
‚Ä¢ Medical electrical equipment needs special precautions regarding electromagnetic compatibility (EMC) and needs to be installed and placed into service according to EMC guidelines provided.  
a. Portable and mobile radio frequency (RF) communications equipmen t can affect medical 
electrical equipment.  
b. Investigators and site personnel should assure the NURO system is used in an appropriate 
environment.  
i. Portable and mobile RF Communications equipment (i .e. cell phones) should not be 
used at close distances.  
ii. Power frequency magnetic fields should be at levels characteristic of a typical 
commercial, hospital or clinic environment.  
‚Ä¢ Always start and restart stimulation at the lowest settings and adjust a s necessary. Do not return to 
any previous setting without observing the patient‚Äôs responses.  
Reporting of adverse events and device deficiencies should follow the requirements outlined in the 
adverse event assessment section of the study protocol.  
There may be risks or side effects which are unknown at this time.  
If a subject becomes pregnant while using the NURO system , there may be risks to her or her unborn baby.  
These risks are currently unknown.  If the Investigators becomes  aware that a subject is pregnant during 
the course of the study, the subject should be exited from the study .   
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 26 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 11.2.  Potential Benefits  
Subjects may not receive any direct medical benefit from participation in this study but subjects will 
receive additional m edical oversight of treatment.  Participation in this study will not provide greater 
benefit than if the subject was  receiving PTNM therapy with the NURO system outside of the study.  
Information from this study might help researchers further understand PT NM therapy.  The benefit to 
subjects participating in this study, and to future patients, resides in the knowledge gained from this 
study related to the safety and efficacy of this therapy  when used in OAB drug na√Øve patients . 
11.3.  Risk-Benefit Rationale  
Partic ipation in this study will not expose the subject to greater risks than if he/she were receiving PTNM 
therapy with the NURO system outside of the study. There might be other discomforts and risks related 
to PTNM and/or this study that are not foreseen at this time.  
Subjects may find that some of the questionnaires or completing the urinary voiding and fecal diaries are 
embarrassing.  
12. Adverse Event Assessments  
12.1.  Definitions/Classifications  
Any adverse event meeting the definition of: serious, device related, and/or procedure related as well as  
all device deficiencies will be considered reportable  for this stu dy.   Adverse events and device 
deficiencies are defined as follows: 
Term  General  
Adverse Event (AE)  Any untoward medical occurrence, unintended disease  or injury, or  untoward 
clinical signs (including abnormal laboratory findings) in  subjects, users or other 
persons, whether or not related to the  medical device  under investigation . 
Adverse Device 
Effect (ADE) * Adverse event related to the use of the medical device  under investigation . 
Device Deficiency 
(DD)* Inadequacy of a medical device with respect to its identity, quality, durability, 
reliability, safety or performance. Device deficiencies include malfunctions, misuse or use errors, and inadequate labeling.
 
ÔÇß Malfunctions: Failure of the medical device under investigation to perform 
in accordance with its intended purpose when used in accordance with the instructions for use or Clinical Investigational Plan (CIP)  
ÔÇß Use Error: Act or omission of an act t hat results in a different medical 
device response than intended by the manufacturer or expected by the user 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 27 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 SERIOUSNESS  
Serious Adverse 
Event (SAE)*    An adverse event that  
a) led to a death,  
b) led to a serious deterioration in the health of the subject, that either 
resulted in:  
1. a life-threatening illness or injury, or  
2. a permanent impairment of a body structure or a body function, or  
3. in-patient or prolonged hospitalization, or  
4. medical  or surgical intervention to prevent life threatening illness or 
injury or permanent impairment to a body structure or a body 
function.  
c) led to fetal distress, foetal death or a congenital abnormality or birth defect.  
 
Note:  A planned hospitalization for pre -existing condition, or a procedure required by the 
CIP, without a serious deterioration in health, is not considered to be a serious adverse 
event.  
Serious Adverse 
Device Effect 
(SADE) *    Adverse device effect that resulted in any of the consequences characteristic of a 
serious adverse event  
Unexpected Serious Adverse Device 
Effect (USADE) * Serious adverse device effect which by its nature, incidence, severity or outcome 
has not been identified.  
RELATEDNESS  
Relationship of 
Adverse Events  The relationship of the adverse event to the study treatment (device, therapy) 
will be described using the following terms:  
‚Ä¢ Not related  
‚Ä¢ Unlikely 
‚Ä¢ Possible 
‚Ä¢ Probable  
‚Ä¢ Causal relationship  
*Reportable  event categories that will be c ollected during this study  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 28 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 12.2.  Reporting of Adverse Events  
Any adverse event meeting the definition of serious, device related, and/or procedure related as well as 
all device deficiencies as defined in above  will be considered reportable for this study.  The procedure is 
defined as each PTNM therapy session.   
Worsening of OAB symptoms will be collected as part of the efficacy measures and are not considered a reportable adverse event.  
All reportable adverse events will be classified using the following responsibility matrix:   
Event Classification Responsibilities  
What is Classified  Who Classifies  Classification Parameters  
Relatedness  Investigator Procedure related  
Device related  
Other  
USADE potential  Medtronic  USADE  
Seriousness  Investigator  SAE/SADE  
Diagnosis  Investigator Based on presenting signs and symptoms and 
other supporting data  
Medtronic  MedDRA term assigned based on the data 
provided by investigator  
 
All reportable  adverse events must be recorded in the subject‚Äôs medical record and on the Adverse Event 
and/or Device Deficiency eCRF and promptly reported to Medtronic.  IRB reporting must be completed in 
accordance with the policies of the governing IRB .    
Reports of adverse events and device deficiencies will include the following information, at a minimum:  
‚Ä¢ Date of event  
‚Ä¢ Diagnosis or description of the event  
‚Ä¢ Assessment of the seriousness and relationship to the product(s) under study  
‚Ä¢ Treatment  
‚Ä¢ Outcome and date or resolution  
It is the responsibility of the Investigator to identify the occurrence of reportable adverse events and 
device deficiencies and to ensure the required information is accurately documented on the eCRF.  
The clinical course of each adverse event must be followed until resolution or subject discontinuation 
from the study , whichever comes first .  ‚ÄúOngoing‚Äù adverse events and device deficiencies must be 
assessed at each protocol required visit, and new or updated information must be documented on the 
Adverse Event and Device Deficiency  eCRF a nd promptly reported to Medtronic and if applicable to the 
IRB.  
If necessary, the Investigator may report to the sponsor initially by telephone or email and follow -up with 
completed eCRFs and, if possible, copies of source documentation regarding the event (e.g., 
physician/nurse notes or summaries).    
Medtronic study personnel   will promptly review all reported adverse events and device deficiencies  and 
if necessary request clarification  and/or additional information from the Investigator.  If Medtronic 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 29 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 disagrees with the Investigator‚Äôs assessment of the adverse event  relationship to device and/or 
procedure , Medtronic study personnel will document the disagreement and report or ensure rep orting of 
both opinions to IRB  as necessary.  All reported adverse events and device deficiencies will be reviewed 
by a Medtronic Medical Monitor  to ensure consistent reporting.  
13. Data Review Committees  
This study will not use a Clinical Events Committee or Data Monitoring Committee.  Instead, all reported 
adverse events  and device deficiencies will be reviewed  by a Medtronic Medical Monitor  to ensure 
consistent reporting . 
14. Statistical Design and Methods  
14.1.  General Statistical Considerations  
14.1.1.  Study Sample Size J ustification  
This study is to evaluate the reduction from baseline in the number of UUI episodes per day after the 
12th PTNM therapy session .  The OrBIT trial by Peters et al (2009)5 compared the effectiveness of PTNS  
to extended -release tolterodine. This study reported an  average reduction of UUI at 12 weeks compared 
to baseline in  the PTNS arm was 1 episode per day with a standard deviation of 2.2.  The following 
assumptions were used for the sample size calculations: reduction of 0.75 UUI episodes/day from 
baseline, one -sample t -test with two -sided Œ±=0.05 , 90% power , and an estimated standard deviation of  
2.2 incontinence episodes/day.   Based on these assumptions, a sample size of 93 subjects would be required to demonstrate a statistically significant reduction from baseline. To account for an attrition  of 
approximately 20%  during the course of the study , a sample size of up to 120 subjects is required for  
this study.  
The sample size requirement of 93 for the primary objective is also adequate to assess  the secondary 
objectives of number of voids per day and quality of life measured by OABq. In the OrBIT trial by Peters 
et al (2009)
5, the average reduction of voids at 12 weeks compared to baseline in  the PTNS arm was 2.4  
voids per day with a standard dev iation of 4.0 . Based on a one-sample t -test, with Œ±=0.05 two-sided, 
90% power , 44 subjects with UF are required to demonstrate a statistically significant reduction from 
baseline if using a conservative estimate of a reduction of 2.0 voids per day with a standard deviation of 4.0. In the InSite study, among all implanted subjects 63% of the urinary incontinence (UI) subjects had both UI and UF at baseline.
29 Therefore, 93 subjects should ensure the sample size needed for the 
secondary objective of UF based on this assumption.    
In the OrBIT trial by Peters et al (2009)5, the average improvement from baseline of HRQL from OABq for 
PTNS  at 12 weeks was 25.3 ¬±21.5. Based on a one-sample t -test, with Œ±=0.05 two -sided, 90% power , 
15 subjects are required to demo nstrate a statistically significant reduction from baseline when using a 
conservative estimate of average improvement of 20 points at 12 weeks with a standard deviation of 22. Therefore, 93 subjects should ensure the sample size need for the secondary objective of OABq.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 30 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 14.1.2.  Description of Baseline variables  
Summary statistics will be provided for baseline variables.  
14.1.3.  Center Pooling  
Data from all study centers will be pooled for the analysis. There are no planned statistical methods to 
test for treatment differences among centers.  The study will be conducted at approximately  15 sites in 
the US.  Initial site enrollment is not planned to exceed 20%  of the total number of subjects that are 
qualified for the study ; however this may be increased based on the Sponsor‚Äôs discretion.  This is 
intended to reduce the possibility that a site with atypical results will be overly influential in the overall 
study results.   
14.1.4.  Special Considerations  
No adjustments for multiple analyses will be made for this study.  
14.1.5.  Interim A nalys es 
No interim analysis is intended  for this study.  
14.1.6.  Reports  
Periodic reports will be provided to each site‚Äôs IRB. A final report will be generated for this study. 
Relevant tables of statistical results and graphs will be generated for inclusion in the final report. Any 
change from the original statistical plan will be summarized.  
14.2.  Demographics  
Summary statistics for demographic variables will be presented . 
14.3.  Primary Objective 
This study will assess the efficacy of PTNM on UUI episodes collected using a voiding diary. The primary 
objective is to demonstrate a statistically significant reduction between  baseline and following the 12th 
PTNM therapy sessions in the number of UUI episodes per day.  
Hypothesis  
Ho: Œº12th PTNM therapy session = Œºbaseline  
Ha: Œº12thPTNM therapy session ‚â† Œºbaseline 
Where Œºbaseline and Œº12th  PTNM therapy session are average UUI episodes per day at baseline and 
following the 12th PTNM therapy session respectively.  
Endpoint definition  
The average U UI episodes per day collected at baseline and following the 12th  and final PTNM therapy  
session will be used as the endpoint for the primary objective.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 31 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 Sample size methods and assum ptions  
This details the sample size justification.  
Data collection and analysis methods  
Diary data collected at baseline and after  the 12th PTNM therapy session will be used for the primary 
endpoint analysis. The paired t -test or the Wilcoxon signed- rank test will be used to evaluate the changes 
after testing for data normality. A statistical test is deemed significant if the P value is less than 0.05. 
Primary ana lysis method will be completers (with no imputation of missing data). Sensitivity analyse s will 
be conducted with the adjusted worst -case method and per protocol analysis . 
Determination of subjects for analysis  
Subjects with diary data from both baseline and  the 12th PTNM therapy session will be included in the primary analysis for this objective.  
In additional to the primary analysis, two sensitivity analyses will be performed:  
‚Ä¢ Adjusted worst -case analysis, in which,  
a. For subjects who received the study therapy and withdrew early due to device- related 
adverse events, or treatment unsuccessful, the 12th PTNM therapy session data point 
will be set to subject‚Äôs baseline assessment.  
b. For subjects who received the study therapy and exit the study early due to all other 
reasons (i.e. adverse events not related to the device), and for subjects who missed the 12th PTNM therapy session or fail to provide the relevant data for 12
th PTNM 
therapy session, the Last Observation Carried Forward (LOCF) method will be used  to 
impute the missing data.  
c. Subjects who exit the study prior to the initial NURO PTNM therapy session will be excluded from this sensitivity analysis  
‚Ä¢ Per protocol sensitivity analysis which will be based on the completers dataset, but will 
exclude  those subjects who take OAB medications in the study . Use of OAB medications will 
be captured as a  protocol deviation.  
Reduction in number of UUI episodes from baseline will be summarized for each follow up visit when the 
diary data is collected with no imputation of missing data (completers analysis).  
14.4.  Secondary Objectives  
Secondary objectives are to assess:  
‚Ä¢ Reduction from baseline  through 12 PTNM therapy sessions in number of voids per day  
‚Ä¢ Change from baseline  through 12 PTNM therapy sessions in quality of life  as measured 
by the OABq Questionnaire  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 32 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 14.4.1.  Secondary Objective #1  
To assess the reduction in number of voids per day from baseline through 12 PTNM therapy session s. 
This objective will be assessed in subjects with > 8 voids per day at baseline. Number of voids collected 
from baseline and the 12th PTNM therapy session  will be used for analysis of this objective. Subjects with 
diary data from both baseline and 12th PTNM therapy session will be included in the analysis.  A paired t -
test or the Wilcoxon signed -rank test will be used to evaluate the changes after 12 PTNM therapy session  
from baseline after testing for data normality.   
In additional to the primary analysis which includes subjects with diary data from baselin e and 12th 
PTNM therapy session, the same sensitivity analyses as described in primary objective will be performed 
for secondary objective #1.  
Reduction in number of voids per day from baseline will also be summarized by the PTNM session when the diary dat a is collected.  
14.4.2.  Secondary Objective # 2 
To assess the change from baseline through 12  PTNM therapy sessions in quality of life  as measured by 
the OABq Questionnaire. This objective will be assessed in subjects with OABq data at baseline and after 
12th PTNM  therapy session . The paired t -test or the Wilcoxon signed- rank test will be used to evaluate 
the changes after the 12th PTNM therapy session  from baseline after testing for data normality.   
In additional to the primary analysis which includes subjects wit h diary data from baseline and 12th 
PTNM therapy session, the same sensitivity analyses as described in primary objective will be performed 
for secondary objective #2.  
Improvement in OABq  from baseline will also be summarized at by the PTNM session when this data is 
collected.  
14.5.  Additional Measures  
Additional measures include:  
‚Ä¢ Incidence of device -related and therapy -related  adverse events  
‚Ä¢ Nocturia / Nighttime voiding frequency  
‚Ä¢ Urgency including the Urgency Perception Scale (UPS)  
‚Ä¢ Patient-reported Outcomes:  
ÔÇß Self-Assessment Goal Achievement Questionnaire  (SAGA) 
ÔÇß Patient Perception of Bladder Condition  (PPBC) 
ÔÇß Patient Global Impression of Improvement (PGI-I) 
Nocturia, nighttime voiding frequency and urgency are collected through voiding diaries and patient reported outcomes. Reductions in nocturia, nighttime voiding frequency and urgency from baseline will 
be summarized by the PTNM session when the data is collected.  
Additional quality of li fe measures including PPBC,  UPS, PGI -I and SAGA are collected in this study. 
These data will be summarized  by the PTNM session when data is collected.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 33 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 Reportable adverse events will be summarized for all subjects who receive the therapy.  
Fecal incontinen ce diaries will be collected for subjects with dual incontinence.  No analysis is pre -
specified for dual incontinence  data.  The intent of collecting this information is to inform future study 
designs.  
15. Ethics  
15.1.  Statement (s) of Compliance  
The study will be conducted in accordance with this protocol, the ethical principles that have their origin 
in the Declaration of Helsinki, all applicable regulatory requirements (21CFR¬ß50 Protection of Human Subjects , 21CFR¬ß56 IRB, and 21CFR¬ß 803 Medical Device Reporting ), and according to GCP.  The 
principles of the Declaration of Helsinki have been implemented in this study by means of the patient informed consent process, IRB approval, risk benefit assessment, study training, clinical trial registration, and publication p olicy.  Study Investigators will be required to sign an Investigator Agreement stating 
their intent to adher to applicable regulations . 
The study will not begin at any site until an  IRB letter approving the protocol and the ICF is received by 
Medtronic.    
Details related to stipends provided to study subjects are outlined in the subject  ICF.  
16. Study Administration  
16.1.  Monitoring  
Medtronic is responsible for ensuring the proper conduct of this study in terms of adherence to applicable regulations, protocol compl iance, and the validity and accuracy of the study data entered on CRFs.  The 
Principal Investigator and site personnel will provide the Medtronic monitor(s) with complete access to 
primary source data (eg, paper and electronic hospital/clinical charts, app ointment books, laboratory 
records) that support the data on the CRFs as well as other documentation supporting the conduct of the study.  The monitor will perform source data verification and routine reviews of study -related regulatory 
documents during scheduled monitoring visits and work to secure compliance should any deficiencies be observed. The monitoring plan contains the strategy for frequency of monitoring visits and source data 
verification to be performed for this study.  
16.2.  Medtronic Representative Role  
Medtronic representatives may participate in the conduct of the study to the extent listed below.   
Medtronic representatives can provide technical support to the investigator and other health care 
personnel as needed during study  visits.  This support may include the training of site personnel on use of 
the Medtronic equipment or the protocol -related procedures and forms.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 34 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 In addition, Medtronic personnel can perform certain activities to ensure study quality.  These activities 
may include:  
‚Ä¢ Observing testing or medical procedures to provide information relevant to protocol completion  
‚Ä¢ Reviewing collected data and study documentation for completeness and accuracy  
Medtronic personnel will not:  
‚Ä¢ Practice medicine  
‚Ä¢ Provide medical diagnosis or treatment to subjects  
‚Ä¢ Discuss a subject‚Äôs condition or treatment with a subject without the approval and presence of 
the health care provider.  
‚Ä¢ Complete CRFs or make entries in the subject‚Äôs medical record  
16.3.  Data Management  
Medtronic personnel will perform routine edit and consistency checks for items such as missing data or 
inconsistent data.  Identified data inconsistencies will be resolved by use of data discrepancies; 
investigators and site personnel will review data discrepancies and respond to the discrepancies in a 
timely manner.  The resolved discrepancy will become a part of the eCRF record for the subject.  
The Oracle Clinical Remote Data Capture (RDC)  system which is 21 CFR¬ß11 Part E compliant controls user 
access, and ensures data integrity. This system is a fully validated system. The RDC system maintains an audit trail of entries, changes or corrections in eCRFs. User access will be granted to each individual based on his or her delegation of authority  and completion of required training . If a person only 
authorized to complete eCRFs makes changes to an already signed eCRF, the system will require the Principal Investigator, or authorized delegate, to re -sign the eCRF.  
The Principal Investigator, or designated representative, is responsib le for the data submitted and must 
review all data for accuracy and provide his/her approval  of the eCRF and sign each form with an 
electronic signature .  
16.4.  Direct Access to Source Data/Documents  
Medtronic or third-party auditors representing Medtronic may perform clinical site audits to verify the 
performance of the monitoring process and study conduct, and to ensure compliance with applicable regulations.  Representatives for regulatory bodies such as the  FDA may also perform site inspections 
related to th is clinical study.  The Principal I nvestigator, site personnel, and institution will provide 
auditors with direct access to primary source data and all study -related documentation.  
In accordance with GCP and regulatory requirements, Medtronic will investigate suspected cases of fraud.  
16.5.  Confidentiality  
Subject confidentiality is assured through the use of subject identification numbers, use of initials only, and the de -identifying of photocopied or records  obtained by the Sponsor.  In addition to  the review of 
records on site, release of de -identified records to Medtronic may be necessary, such as in the evaluation 
of adverse events.   
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 35 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 For purposes of monitoring this study, access to clinic and hospital records must be available to 
Medtronic, agents of Medtronic (e.g. CRO), the FDA, and other regulatory agencies.   
Health Insurance Portability and Accountability Act  (HIPAA ) language will be required to be included at 
every site.   HIPAA language may be include d within the ICF template.  
16.6.  CIP Amendments  
Protocol amendments may be initiated by Medtronic to address changes to the conduct of the study.  
Protocol amendments must be approved by Medtronic and submitted to the IRBs; protocol amendment 
approval and appro val of any associated changes to the informed consent document must be obtained 
prior to implementation of the amendment except:  
‚Ä¢ When necessary to eliminate an immediate/or apparent immediate hazard to participating  
subjects  
‚Ä¢ When the change involves purel y administrative or logistical aspects of the study  
16.7.  Record Retention  
At a minimum the investigator is responsible for the preparation, review, and retention of the records 
listed below:  
‚Ä¢ Essential correspondence that pertains to the investigation  
‚Ä¢ Records o f each subject‚Äôs case history and exposure to the device.  Case histories include the 
CRFs and supporting data (source documentation), such as:  
o Signed and dated ICFs 
o Medical records, including, for example, progress notes of the physicians, the 
subject‚Äôs hospital chart(s) and the nurses notes  
o All reportable adverse event information  
o Data related to  the PTNM therapy  session  
‚Ä¢ Documentation of any deviation to the protocol, including the date and the rationale for such deviation 
‚Ä¢ Signed Investigator Agreement and curriculum vitae  for all Investigators  
‚Ä¢ The protocol and any amendments  
The Principal I nvestigator is responsible for ensuring that all essential study documentation is retained 
and accessible for a minimum of 2 years following completion of the study.  The Principal Investigator will 
ensure that essential study documents are not destroyed until written permission has been obtained from 
Medtronic.  Medtronic will be notified in writing of any transfer of study documentation.   
16.8.  Publication and Use of Info rmation  
Medtronic intends to publish the results from the RESET  Study in a timely manner upon study completion .  
These publication activities may include abstracts, presentations/ posters to scientific meetings, and 
manuscripts.    
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 36 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 Investigators who gathered  data for this study (ie, enrolled subjects and complied with the protocol) may 
be asked to write or contribute to the writing of abstracts and manuscripts based on the results of this 
study.  Principal investigators who meet the study -specific criteria above will be considered for 
abstract/manuscript authorship if they meet the International Committee of Medical Journal Editors, 
Ethical Considerations in the Conduct and Reporting of Research criteria available via the following link: 
http://www.icmje.org .  Specifically, authorship credit should be based on the following and should meet 
all criteria listed below:   
‚Ä¢ Substantial contributions to conception or design ;or the  acquisition, analysis and interpretation of 
data for the work ;  
‚Ä¢ Drafting the article or revising it critically for important intellectual content; and  
‚Ä¢ Final approval of the version to be published ; and.  
‚Ä¢ Agreement to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and resolved.  
Medtronic employees who meet the International Committee of Medical Journal Editors criteria for 
authorship will have the right to authorship.  
All contributors who do not meet the criteria for authorship are to  be listed in an acknowledgments 
section according to the guidelines of the applicable scientific journal. Examples of those who might be acknowledged include a person who provided purely technical help, writing ass istance, or a department 
chair who provided only general support.  
16.9.  Suspension or Early Termination  
Medtronic reserves the right to suspend or terminate the study at any time.  Reasons may include, but are not limited to, the following:  
‚Ä¢ Insufficient enrollme nt to complete the study within the expected timeframe 
‚Ä¢ Identification of unacceptable safety profile; suspicion of an unacceptable risk will result in a 
suspension, confirmation of an unacceptable risk will result in termination  
‚Ä¢ Product performance/product  supply issues  
Medtronic reserves the right to suspend or terminate the study at an individual site .  Reasons may 
include, but are not limited to, the following:  
‚Ä¢ Noncompliance with the protocol  
‚Ä¢ Serious or repeated deviations at the site  
‚Ä¢ Failure to implement required corrective and preventive actions  
‚Ä¢ Insufficient enrollment to complete the study within the expected timeframe 
‚Ä¢ Loss of appropriately trained site personnel  
Investigators are required to notify the IRB of study suspension/termination.  Subjects will be notified by 
the investigator of suspension/termination due to unacceptable risk or of termination due to any other cause.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 37 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 17. References  
1. Gormley AE, Lightner, DJ Diagnosis and Treatment of Overactive Bladder (Non -Neurogenic) in 
Adults: AUA/SUF U Guideline Amendment. J Urol. 2015 ; 193(5) 1572 -1580 
2. Govier FE, Litwiller S, Nitti V, et al. Percutaneous afferent neuromodulation for the refractory 
overactive bladder: results of a multicenter study. J Urol. 2001 ; 165: 1193- 1198 
3. van Balken MR, Vandoninc k V, Gisolf KW, et al. Posterior tibial nerve stimulation as 
neuromodulative treatment of lower urinary tract dysfunction.  J Urol. 2001 ; 166: 914 -918 
4. Karademir K, Baykal K, Sen B, et al. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. Scand J Urol Nephrol. 2005 ; 39: 230 -233 
5. Peters KM, MacDiarmid SA, Randomized trial of percutaneous tibial nerve stimulation versus 
extended -release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 
2009; 182(3): 1055- 1061  
6. Finazzi -Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor 
overactivity incontinence are not due to a placebo effect: a randomized, double -blind, placebo 
controlled trial. J  Urol. 2010 ; 184: 2001 -2006 
7. Peters KM, Carrico DJ, Randomized trial of percutaneous tibial nerve stimulation versus Sham 
efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 
2010; 183(4): 1438- 1443 
8. Vecchioli -Scaldazza C, Morosetti C, Berouz A, et al. Solifenacin Succinate versus Percutaneous 
Tibial Nerve Stimulation in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Crossover Study. Gynecol Obstet Invest. 2013 ; 75: 230 -234 
9. Burton C, Sajj a A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for 
overactive bladder: a systematic review and meta -analysis. Neurourol Urodyn . 2012; 31:1206-
1216 
10. Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous Tibial Nerve Stimulat ion (PTNS) efficacy in 
the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol . 2013; 13:61  
11. Monga AK, Tracey MR, Subbaroyan J. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract d ysfunction. Int Urogynecol J . 2012; 23:993- 1005 
12. Moossdorff -Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on 
adult patients with overactive bladder syndrome: a systematic review. Neurourol Urodyn 2013; 32:206- 214 
13. Schreiner L,  Santos TG, Souza AB, et al. Electrical stimulation for urinary incontinence  in women: 
a systematic review. Int Braz J Urol 2013; 39:454- 464 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 38 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 14. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A., Petri E, Rizk DE, 
Sand PK & Schaer GN. An International Urogynecological Association (IUGA)/International 
Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. 
Neurourology and Urdynamics  2010;  29, 4- 20  
15. EAU Guideline on Urinary Incontinence.  http://uroweb.org/guideline/urinary -incontinence .  2014 
16. Preyer O, Umek W, Laml T, Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controll ed trial. European Journal of Obstetrics & 
Gynecology and Reproductive Biology 2015; 191: 51- 56 
17. Abrams P, Cardozo L, Khoury S, Wein A.  Incontinence. Fourth Edition. Paris: Health Publication, 2009.  
18. Coyne KS, Gelhorn H, Thompson C, Kopp ZS, & Guan Z. The psychometric validation of a 1 -week 
recall period for the OAB -q. Int Urogynecol J. 2011; 22(12):1555 -63 
19. Cardozo, L., Coyne K S and Versi E. Validation of the Urgency Perception Scale.  BJU International 2005; 95:  591‚Äì596. doi: 10.1111/j.1464- 410X.2005.05345.x  
20. Freeman R, Hill S, Millard R, Slack M and Sutherst J.  Reduced Perception of Urgency in Treatment of Overactive Bladder with Extended -Release Tolterodine.  The American College of 
Obstetricians and Gynecologists 2003; 103(2): 605-611   
21. Brubaker, L , Piault EC, Tully SE, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp Z S, Khullar V, 
Kelleh er CJ and Trocio J.  Validation study of the Self -Assessment Goal Achievement (SAGA) 
questionnaire for lower urinary tract symptoms. International Journal of Clinical Practice  2013; 
67: 342‚Äì 350. doi: 10.1111/ijcp.12087  
22. Hullfish KL , Bovbjerg VE , Gurka  MJ, and Steers  WD.  Surgical vs. non -surgical treatment in 
women with pelvic floor dysfunction: Patient -centered goals at one year. J Urol. 2008; 179(6): 
2280‚Äì 2285 
23. Khullar V, Marsc hall-Kehrel D, Espuna -Pons M, Kelleher C.J, Tully SE, Piault EC, Brubaker L, 
Fianu- Jonasson A, Weinstein D, Bergqvist A, Kvasz M.  European content validation of the Self -
Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder.  
International Urogynecology Journal and Pelvic Floor Dysf unction.  2013; 24(9): 1529 -153  
24. Zecca  C, Digesu  GA, Robshaw  P, Puccini  F, Khullar  V, Tubaro  A and Gobbi  C.  Motor and sensory 
responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower 
urinary tract  symptoms treated in daily practice.  European Journal of Neurology 2014 ; 21: 506 ‚Äì
511 
25. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condit ion (PPBC): a single -item global measure for patients with overactive bladder. Eur Urol. 
2006; 49(6):1079- 1086 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 39 of 39 
Confidential  
Version 1.0            Medtronic RESET Protocol  June 2 , 2016  
 26. Vecchioli -Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succintate 
versus percutaneous tibial nerve stimulation in wom en with overactive bladder syndrome: Results 
of a randomized controlled crossover study. Gynecologic and Obstetric Investigation 2013; 
75(4):230 -234 
27. Yalcin I, Bump R. Validation of two global impression questionnaires for incontinence. Am J 
Obstet Gynecol.  2003;189(1):98- 101 
28. Tincello D, Owen R, Slack M, Abrams K. Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study. BJOG 2013;120:212‚Äì 216. 
29. Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 2016;35(2):246-51.  
18. Appendices  
None 